SAN FRANCISCO (TheStreet) -- It's rare to hear a biotech CEO mention a competing company by name when speaking in public. Like politicians, CEOs would rather acknowledge their rivals with generalities. BioMarin Pharmaceuticals (BMRN - Get Report) CEO Jean-Jacques Bienaime feels differently because he just went directly after Sarepta Therapeutics (SRPT - Get Report) at the J.P. Morgan Healthcare Conference.

Included in Bienaime's investor presentation is two slides making a direct data comparison between BioMarin's (soon to be) Duchenne muscular dystrophy drug drisapersen and Sarepta's competing DMD drug eteplirsen. The still-experimental drugs have never been studied head to head in a clinical trial, of course, but that didn't stop BioMarin from attempting to show how drisapersen was more effective than eteplirsen.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.